Aurobindo Pharma’s wholly owned subsidiary -- Eugia Pharma Specialities’ Unit-I, a Formulation manufacturing facility, situated at Kolthur Village, Telangana has been classified as ‘official action indicated’ (OAI) by the United States Food and Drug Administration (USFDA). The USFDA had conducted inspection of the said unit from February 16 to February 27, 2026 and concluded the inspection with 4 observations.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
